Filing Flows › TG Therapeutics (TGTX) › Q4 2024
TG Therapeutics (TGTX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 3, 2025
TG Therapeutics (TGTX) reported revenue of $108M for the fourth quarter 2024 (Q4 2024), +146% from a year earlier and +29% from the quarter before. Operating margin was 27.7%, net earnings $23.3M (21.6% of revenue).
TG Therapeutics, Q4 2024: revenue $108M (+146% year over year), operating margin 27.7%, net earnings $23.3M, operating cash flow −$25.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $108M | +29% | +146% |
| Operating profit | $29.9M | +141% | — |
| Net earnings | $23.3M | +501% | — |
| Operating cash flow | −$25.6M | — | — |
What changed
Revenue was $108.2M in Q4 2024, up 146% year over year and up 29% from the previous quarter. Product was the largest line at 99% of revenue.
Operating profit was $29.9M, a 27.7% margin (up 56.1 points year over year). Total costs grew 39% against revenue growth of 146%. The fastest-growing cost line was Cost of revenue (+96%). Net earnings were $23.3M. The effective tax rate was 8.3%.
Operating cash flow was −$25.6M. Non-cash charges added back $9K of depreciation and amortization and $11.9M of share-based compensation. Working capital and other items used $60.9M. Capital expenditures of $21K exceeded it, leaving free cash flow of −$25.7M.
Questions
What was TG Therapeutics' revenue in the fourth quarter 2024?
TG Therapeutics (TGTX) reported revenue of $108M for the fourth quarter 2024 (Q4 2024), +146% from a year earlier and +29% from the quarter before.
Was TG Therapeutics profitable in the fourth quarter 2024?
Operating profit was $29.9M (27.7% of revenue) and net earnings $23.3M.
Source: TG Therapeutics 10-K on SEC EDGAR.